Session » Abstracts: Immunological Complications of Medical Therapy
- 4:00PM-5:30PM
-
Abstract Number: 2510
Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1
- 4:00PM-5:30PM
-
Abstract Number: 2513
Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
- 4:00PM-5:30PM
-
Abstract Number: 2514
Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
- 4:00PM-5:30PM
-
Abstract Number: 2509
Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias
- 4:00PM-5:30PM
-
Abstract Number: 2511
Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies
- 4:00PM-5:30PM
-
Abstract Number: 2512
Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis